Skip to main content
logo
AptaBio Therapeutics Inc. (KOSDAQ:293780)
South Korea flag South Korea · Delayed Price · Currency is KRW
6,460.00
-160.00 (-2.42%)
Sep 4, 2026, 3:30 PM KST

AptaBio Therapeutics Financials Overview

Millions KRW. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
4,7533,6983,361323.8748.35
Revenue Growth
52.91%10.03%937.76%569.80%-
Gross Profit
2,2441,289273.6961.0637.21
Operating Income
-18,752-15,536-20,715-16,904-9,507
Net Income
-14,869-16,346-29,378-11,866-10,565
Earnings Per Share
-541.07-607.49-1248.00-532.16-474.00
EPS Growth
-----

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
15,72517,19031,51552,88517,015
Total Debt
4,9134,4227,52113,934366.03
Net Cash (Debt)
10,81212,76823,99438,95116,649
Net Cash Growth
-23.18%-46.79%-38.40%133.95%-
Net Cash Per Share
393.43474.511019.291746.78746.98

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-17,373-15,276-12,160-14,095-6,833
Capital Expenditures
-30.87-58.67-240.16-1,345-1,041
Free Cash Flow
-17,404-15,335-12,400-15,440-7,874
Free Cash Flow Growth
-----

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
47.21%34.84%8.14%18.86%76.95%
Operating Margin
-394.53%-420.14%-616.35%-5219.25%-19661.23%
Pretax Margin
-291.66%-414.83%-827.22%-4536.36%-21849.26%
Profit Margin
-312.83%-442.04%-874.09%-3663.98%-21849.26%
FCF Margin
-366.15%-414.69%-368.94%-4767.39%-16284.04%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22
Forward PE
-78.1078.1078.1078.10
PS Ratio
38.1867.9750.95623.114911.46